My 5 Top Dividend Stocks to Buy Hand Over Fist in 2024 | The Motley Fool (2024)

The three major indexes gave investors a taste of the downs and ups of investing over the past couple of years, reaching into bear territory in 2022 and then rising in the double digits last year. It's impossible to predict with 100% certainty what the market will do this year, but there is reason to be optimistic about what's ahead. That's because history shows us bear markets always lead to better market times, and those times of strength -- bull markets -- last longer than times of weakness.

In any case, there's a type of stock that could offer great rewards no matter what the market is doing. I'm talking about dividend stocks, which pay you passive income each year just for owning them. In bull markets, you'll often benefit from these stocks' market performance and the extra income -- and in more difficult times, the dividend payments alone could bolster your portfolio. Here are my five top dividend stocks to buy hand over fist in 2024.

My 5 Top Dividend Stocks to Buy Hand Over Fist in 2024 | The Motley Fool (1)

Image source: Getty Images.

1. Johnson & Johnson

Johnson & Johnson (JNJ -0.04%), as a Dividend King, has lifted its payment for more than 50 consecutive years. This track record shows rewarding shareholders is important to the company, so it's reasonable to expect the policy to continue.

J&J pays a dividend of $4.76 per share, representing a yield of 2.95%, surpassing that of the S&P 500. And the healthcare giant, generating more than $15 billion in free cash flow, has what it takes to financially support dividend increases.

Importantly, even more growth may be right around the corner for this company. Last year, J&J spun off its slower growth consumer health business to focus on its higher growth pharmaceuticals and medtech businesses. The company predicts it will launch 20 new drugs and 50 expansions of current products by 2030. And one-third of medtech sales will come from new products by 2027. So, buying J&J shares now could offer you a great combination of safety -- thanks to dividends -- and growth.

2. Coca-Cola

Coca-Cola (KO 0.35%) also makes the list of Dividend Kings after its many decades of dividend growth. The company pays $1.84 per share at a yield of 3.06%, like J&J, surpassing the yield of the S&P 500.

The world's biggest non-alcoholic beverage maker's cash dividend payout ratio shows it pays out 76% of free cash flow as dividends. And the company's rising free cash flow indicates this clearly is sustainable.

My 5 Top Dividend Stocks to Buy Hand Over Fist in 2024 | The Motley Fool (2)

KO Cash Dividend Payout Ratio data by YCharts

What drives this cash flow growth is Coca-Cola's high-quality business, selling its eponymous beverage and many other top brands -- from Dasani water to Minute Maid juices -- that keep customers coming back. Coca-Cola's solid moat, or competitive advantage, is this brand strength, and it helped the company continue to increase earnings even as higher inflation weighed on the consumer's buying power last year.

So, you can count Coca-Cola to progressively grow earnings and dividends almost regardless of the economic environment, making it a top stock to buy and hold for the long term.

3. Abbott Laboratories

I like Abbott Laboratories (ABT -0.39%) for its long history of dividend growth -- meet yet another Dividend King -- as well as its diversified healthcare business.

Let's talk dividend first. Abbott pays a dividend of $2.20 per share at a yield of 1.93%, surpassing the yield of the S&P 500, and like the companies I've mentioned above, Abbott has the solid free cash flow to sustain dividend growth. So, when you buy this stock, you can imagine your passive income increasing year after year.

My 5 Top Dividend Stocks to Buy Hand Over Fist in 2024 | The Motley Fool (3)

ABT Free Cash Flow data by YCharts

As for Abbott's business, the company includes four units: medical devices, diagnostics, nutrition, and established pharmaceuticals. The charm of this is if one faces a particular headwind, the others can compensate -- this has happened with diagnostics, as the company's covid tests went from soaring to declining revenue. In the recent quarter, excluding the negative impact of covid tests, Abbott's sales rose more than 13% to $10 billion -- and all four businesses posted double-digit gains.

So, using Abbott's historical performance as a guide, you can count on steady earnings growth as you collect more and more passive income year after year.

4. AbbVie

AbbVie (ABBV -0.44%) made its debut back in 2013 when Abbott spun off its pharmaceuticals business, and since, the new company has increased its dividend 285%. Today, AbbVie pays a dividend of $6.20 per share, at a yield of 3.80%.

In the most recent earnings call, AbbVie said dividend growth remained a priority, even today as it goes through a significant transition. AbbVie's top-selling drug Humira faces biosimilar competition, and that equals declining revenue. But the company has groomed two newer immunology drugs -- Rinvoq and Skyrizi -- to take over and together surpass Humira's peak revenue by the end of the decade.

Rinvoq and Skyrizi, heading for $11.6 billion in sales for the full year 2023, are on the right path. On top of this, AbbVie also has a full portfolio of other major drugs in areas including neurosciene and aesthetics, and a promising pipeline too.

All of this means the stock could deliver increasing growth -- and dividends -- as AbbVie approaches its goals.

5. Medtronic

Medtronic (MDT 0.87%) is another company involved in a transition phase that's set to lead to increasing growth. The medical device giant has taken steps to become more efficient, divest slow-growth businesses, and invest in growth areas such as artificial intelligence (AI).

At the same time, Medtronic has committed to making dividend growth a priority. In the company's most recent earnings report, it said it aims to return at least 50% of free cash flow to shareholders each year. In the 2023 fiscal year, it returned $4 billion, or 86% of free cash flow, in the form of dividends and share repurchases.

Medtronic pays a dividend of 2.76, at a yield of 3.20%, and has increased its payouts for more than 45 years. Considering its prioritization of dividend growth, its steps to boost earnings, and the fact that it's very close to becoming a Dividend King, this company makes a top dividend stock to buy hand over fist this year.

Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends Johnson & Johnson and Medtronic and recommends the following options: long January 2024 $47.50 calls on Coca-Cola. The Motley Fool has a disclosure policy.

About Dividend Stocks and Top Picks for 2024

As an enthusiast and expert in finance and investment, I have a deep understanding of the stock market, investment strategies, and the significance of dividend stocks in a well-rounded investment portfolio. I have closely followed the performance of various companies and their dividend policies, and I can provide valuable insights into the potential of dividend stocks for investors.

The article discusses the significance of dividend stocks in a volatile market and highlights five top dividend stocks to consider for investment in 2024. It emphasizes the potential benefits of dividend stocks in both bull and bear markets, underlining their ability to provide passive income and potentially bolster a portfolio during challenging times.

Johnson & Johnson

Johnson & Johnson (JNJ) is recognized as a Dividend King, having consistently increased its dividend payment for over 50 consecutive years. The company's strong track record in rewarding shareholders demonstrates its commitment to sustaining dividend growth.


Coca-Cola (KO) is another Dividend King with a long history of dividend growth. The company's cash dividend payout ratio indicates its ability to sustain dividend growth, supported by its high-quality business and strong brand portfolio.

Abbott Laboratories

Abbott Laboratories (ABT) is also highlighted for its long history of dividend growth as a Dividend King. The company's diversified healthcare business and solid free cash flow position it well to sustain dividend growth, making it an attractive option for investors seeking passive income.


AbbVie (ABBV), a pharmaceutical company, has significantly increased its dividend since its inception in 2013. Despite facing challenges with biosimilar competition for its top-selling drug, the company has promising newer drugs in its pipeline, indicating potential for increasing growth and dividends.


Medtronic (MDT), a medical device giant, is undergoing a transition phase aimed at increasing growth. The company has committed to prioritizing dividend growth and returning a significant portion of free cash flow to shareholders, making it an appealing choice for dividend-focused investors.

These top dividend stocks offer a combination of dividend income and potential for growth, making them compelling options for investors seeking stability and long-term returns in their investment portfolios.

If you have any further questions about dividend stocks or investment strategies, feel free to ask!

My 5 Top Dividend Stocks to Buy Hand Over Fist in 2024 | The Motley Fool (2024)


Top Articles
Latest Posts
Article information

Author: Ray Christiansen

Last Updated:

Views: 6040

Rating: 4.9 / 5 (69 voted)

Reviews: 92% of readers found this page helpful

Author information

Name: Ray Christiansen

Birthday: 1998-05-04

Address: Apt. 814 34339 Sauer Islands, Hirtheville, GA 02446-8771

Phone: +337636892828

Job: Lead Hospitality Designer

Hobby: Urban exploration, Tai chi, Lockpicking, Fashion, Gunsmithing, Pottery, Geocaching

Introduction: My name is Ray Christiansen, I am a fair, good, cute, gentle, vast, glamorous, excited person who loves writing and wants to share my knowledge and understanding with you.